← Leaderboards
Krzysztof W Pankiewicz
Pharmasset, Inc.
$725,009
Attributed
$725,009
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$725,009 · 5
By mechanism
R43$725,009 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionDrug Screening /EvaluationMycophenolic AcidAlcohol OxidoreductasesNicotinamide Adenine DinucleotideDinucleotideAntineoplasticsOxidoreductaseMicroorganism Disease ChemotherapyColon NeoplasmsCytotoxicityDna Directed Rna PolymeraseEnzyme ActivityEnzyme InhibitorsGlucuronidesGuanosine TriphosphateHepatitis CHepatitis C VirusHydroxamateImmunosuppressiveInosine MonophosphateLaboratory MouseNeoplastic CellNucleoside Analog
Grant awards (5)
Novel Class of Compounds for Treatment of HCV Infections$175,000
R43 · FY2003 · AI
Novel agents against West Nile Virus infections$100,000
R43 · FY2003 · AI
NOVEL BENZAMIDE RIBOSIDE ANALOGUES AS ANTICANCER AGENTS$249,998
R43 · FY2001 · CA
NOVEL DIFFERENTIATION AGENTS AGAINST HUMAN LEUKEMIAS$100,010
R43 · FY2000 · CA
NOVEL COFACTOR ANALOGUES AS IMMUNOSUPPRESSANTS$100,001
R43 · FY2000 · AI